Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 176 for:    immunotherapeutic agent | colon cancer

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04108481
Recruitment Status : Not yet recruiting
First Posted : September 30, 2019
Last Update Posted : September 30, 2019
Sponsor:
Collaborators:
Biocompatibles UK Ltd
AstraZeneca
Information provided by (Responsible Party):
Pashtoon Murtaza Kasi, MD, MS, University of Iowa

Brief Summary:
This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS).

Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic Colon Cancer Metastatic Colorectal Cancer Rectal Cancer Liver Metastasis Colon Cancer Colo-rectal Cancer Colorectal Adenocarcinoma Colorectal Neoplasms Liver Metastases Colorectal Carcinoma Drug: Durvalumab Radiation: Yttrium-90 RadioEmbolization Phase 1 Phase 2

Detailed Description:

The purpose of this clinical trial is to find out more about the side effects of immunotherapy with a form of radiation treatment for the cancer in the liver called Yttrium-90 RadioEmbolization (Y90-RE). An immunotherapy drug, durvalumab, will be given intravenously every 2 weeks. Investigators are studying what doses of durvalumab are safe for people in combination with this form of radiation treatment. Patients in this study will receive durvalumab, which is experimental and not approved by the U.S. Food and Drug Administration (FDA) for metastatic colorectal cancer. Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver.

The number of doses of the immunotherapy drug (range: 2 to 5) will depend on the cohort patients are assigned to. There is no placebo. Everyone on the study is treated with immunotherapy alongside Y90-RadioEmbolization.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Accelerated titration design with an expansion phase once MTD is determined to treat up to a total of 18 patients.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial]
Estimated Study Start Date : October 2019
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Y90-RE in combination with immunotherapy (durvalumab)

The treatment phase starts of with the immunotherapy drug (durvalumab) - "priming doses" every 2 weeks prior to patient getting mapped and ready for treatment with Y90-RadioEmbolization.

Post-Y90-RE, treatment is approximately 2 months in combination with fixed doses (750 mg) of durvalumab. The number and timing of doses of durvalumab each patient will receive will depend on the dose level the patient is assigned to (range 2-5 doses of immunotherapy).

A single patient will be treated per dose level until the first dose limiting toxicity (DLT) is recorded. Once the first DLT is recorded, two additional patients are treated at the same dose level and the trial reverts to a standard 3+3 design. Up to 6 patients will be treated at each dose level. The maximum tolerated dose (MTD) will be defined as the highest dose level for which at most 1 out of 6 patients experience a DLT.

Drug: Durvalumab
Immunotherapy
Other Names:
  • IMFINZI
  • MEDI4736
  • MEDI-4736
  • Anti-PDL1

Radiation: Yttrium-90 RadioEmbolization
Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
Other Names:
  • Y90-RE
  • Y90
  • Glass Microspheres
  • yttrium90
  • Y-90 Glass Microspheres




Primary Outcome Measures :
  1. Determine the maximum tolerated dose (MTD) of Yttrium-90 radioembolization combined with immunotherapy durvalumab to treat liver-predominant metastatic colorectal cancer (mCRC) [ Time Frame: Initiation of treatment up to 8 weeks and 2 doses ("priming") of immunotherapy prior to Y90-RE. ]
    MTD will be defined as the highest dose level for which at most 1 out of 6 patients experience a dose-limiting toxicity (DLT) using CTCAE version 5.0.


Secondary Outcome Measures :
  1. Incidence of adverse events (AE) per CTCAE version 5.0 [ Time Frame: Initiation of screening up to 2 years ]
    The number and severity of all adverse events (overall, by dose-level, and by tumor molecular subtype) will be tabulated and summarized.

  2. Determine overall response rate (ORR) [ Time Frame: Up to 2 months post treatment ]
    Overall response rate is defined as the proportion of evaluable patients that have achieved a complete response (CR) or partial response (PR) by RECIST v1.1 as well as mRECIST and iRECIST.

  3. Determine the disease control rate (DCR) [ Time Frame: Up to 2 months post treatment ]
    Disease control rate is defined as the proportion of evaluable patients that have achieved a complete response (CR), partial response (PR), or stable disease (SD) by RECIST v1.1 as well as mRECIST and iRECIST.

  4. Determine liver-specific progression free survival [ Time Frame: Up to 2 months post treatment ]
    Progression free survival is defined as the proportion of evaluable patients that have achieved liver-specific progression free survival (Liver-PFS)

  5. Determine overall progression free survival [ Time Frame: Up to 2 years ]
    Progression free survival is defined as the proportion of evaluable patients that have achieved overall progression free survival (PFS)

  6. Determine overall survival [ Time Frame: Up to 2 years ]
    Overall survival (OS) is defined as the time from randomization to death of any cause.

  7. Determine duration of response [ Time Frame: Up to 2 years ]
    Duration of response (DOR) is defined as the time measurement criteria for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.


Other Outcome Measures:
  1. Circulating tumor DNA - ctDNA - liquid biopsy correlates [ Time Frame: Up to 2 months post treatment ]
    To determine changes in the expression profile and in levels of circulating tumor DNA (ctDNA) in blood pre- and post- treatment

  2. Immune correlates - tissue [ Time Frame: Up to 2 months post treatment ]
    To assess the changes in immune infiltration (TISSUE: tumor-infiltrating lymphocytes - TILs (CD-3, CD-8), PD-L1 and PD-1 expression, pre- and post-Y90-RE and immunotherapy)

  3. Immune correlates - blood [ Time Frame: Up to 2 months post treatment ]
    To analyze serial changes in immune cells (BLOOD) pre- and post-Y90-RE and immunotherapy

  4. Tumor tissue - correlates [ Time Frame: Up to 2 months post treatment ]
    To evaluate mutation burden by whole-exome sequencing pre- and post-treatment (TISSUE)

  5. Tumor tissue - correlates [ Time Frame: Up to 2 months post treatment ]
    To evaluate concomitant expression profile changes through RNA-Seq pre- and post-treatment (TISSUE)

  6. Abscopal effects [ Time Frame: Up to 2 months post treatment ]
    To report on any abscopal effects seen in terms of responses outside the Y90-RE field



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years
  • Histological or cytological confirmation of colorectal cancer with metastasis to the liver. Mismatch repair or microsatellite instability status of the tumor needs to be known. Tumors need to be mismatch repair proficient (for mismatch repair deficient tumors immunotherapy is already approved).
  • Patient must have at least 1 liver lesion measurable as defined in the protocol
  • Must have liver metastases and be appropriate for treatment with Y-90 radioembolization therapy as determined by the treating medical oncologist and interventional radiologist/oncologist, and nuclear medicine physician(s). NOTE: the goal of therapy is safety and parenchymal sparing. Typically, since the treatment is personalized, the goal is to have at least 30% liver parenchymal sparing post treatment.
  • Must have a metastatic focus amendable to biopsy. It is permissible to use same or alternative lesion for biopsy for assessment for tumor response and changes in microenvironment (mandatory pre- and post-Y90-RE biopsy).
  • At least 2 but no more than 3 lines of therapy allowed in metastatic setting. These include at least treatment with a fluoropyrimidine, oxaliplatin, and/or irinotecan-based therapy, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy, unless deemed intolerant or not suitable by the treating oncologist. NOTE: adjuvant and/or maintenance chemotherapy does not count as an additional line of therapy. (Patients with more than 3 lines of therapy are at risk for liver disease from prior systemic therapies and would not be reasonable candidates for Y90-RE).
  • ECOG Performance Status (PS) 0 or 1.
  • Negative serum pregnancy test done ≤7 days prior to registration, for persons of childbearing potential only.
  • Females of childbearing potential (FOCBP), must use appropriate method(s) of contraception. FOCBP are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Additionally, FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with durvalumab plus 5 half-lives of durvalumab (13 weeks) plus 30 days (duration of ovulatory cycle) for a total of 17 weeks post-treatment completion (details in appendix).
  • Men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with durvalumab plus 5 half-lives of durvalumab plus 90 days (duration of sperm turnover) for a total of 25 weeks post-treatment completion (details in appendix).
  • Provide written informed consent.
  • Ability to complete questionnaire(s) by themselves or with assistance.
  • Willingness to provide mandatory blood specimens for correlative research (detailed in protocol).
  • Willingness to provide mandatory tissue specimens for correlative research (detailed in protocol). NOTE: If tissue is deemed inaccessible, patient cannot participate in study.
  • Willingness to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
  • Must have a life expectancy of at least 6 months.

Exclusion Criteria:

  • Any of the following laboratory abnormalities:

    • Hemoglobin <8.0 g/dL
    • Absolute neutrophil count (ANC) <1500/mm3
    • Platelet count <100,000/mm3
    • Total bilirubin >1.5 x ULN (except in subjects with Gilbert Syndrome, who cannot have a total bilirubin > 3.0 mg/dL)
    • Alanine aminotransferase (ALT) and Aspartate transaminase (AST) >2.5 x ULN
    • Serum creatinine > 1.5 x ULN OR
    • Calculated creatinine clearance <30 ml/min using the Cockcroft-Gault formula
  • Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:

    • Pregnant persons
    • Nursing persons
    • Persons of childbearing potential who are unwilling to employ adequate contraception
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Untreated central nervous system (CNS) metastatic disease (including spinal cord and leptomeningeal disease). NOTE: Patients with previously treated CNS metastases that are radiographically and neurologically stable for ≥ 6 weeks are permitted.
  • Uncontrolled intercurrent illness including, but not limited to, autoimmune disease, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements. EXCEPTION: Patients who have adequately controlled autoimmune disease with or without medications are permitted as long as deemed reasonable by treating physician.
  • Received any other investigational agent incorporating chemotherapy and/or biologics within 14 days prior to first dose of durvalumab which would be considered as a treatment for the primary neoplasm. For patients on active treatment, last treatment and 1st dose of Durvalumab should be at least ≥ 14 days. EXCEPTION: Other forms of concurrent observational studies are permitted.
  • Other active malignancy ≤3 years prior to registration. EXCEPTIONS: Non-melanoma skin cancer, lentigo maligna- in-situ, or carcinoma-in-situ of the cervix. Also prior malignancy already treated with curative intent and with no known active disease present would be considered eligible.
  • History of unstable cardiac disease defined as one of the following:

    • Congestive heart failure > class II New York Heart Association (NYHA). (Appendix II)
    • Unstable angina (angina symptoms at rest) or new onset angina (began ≤ 3 months prior to registration)
    • Myocardial infarction ≤ 3 months
    • Uncontrolled cardiac ventricular arrhythmias. EXCEPTION: Subjects that are stable on anti-arrhythmic therapy are eligible.
  • Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment within 14 days of first dose of durvalumab. NOTE: Subjects can be screened during washout period.
  • History of severe allergic reactions (i.e. Grade 4 allergy, anaphylactic reaction from which the subject did not recover ≤ 6 hours of initiation of supportive care)
  • Failure to recover from toxicities from prior anti-cancer therapy, defined as having not resolved to National Cancer Institute (NCI) CTCAE version 5.0 Grade ≤ 1. EXCEPTIONS: Alopecia and laboratory values listed per the exclusion criteria. Also subjects with irreversible toxicity that is not reasonably expected to be exacerbated by any investigational products (i.e. hearing loss) will be permitted.
  • Use of steroids. EXCEPTIONS: Systemic glucocorticoids will be permitted as long as it is ≤20 mg of prednisone equivalent. Topical steroids, such as bronchodilators and local steroid injections are also permitted if clinically required.
  • Patients with renal failure currently requiring dialysis of any kind.
  • Active HIV, Hepatitis B or C with uncontrolled disease. EXCEPTION: Patient with non-active, controlled disease will be allowed to participate in study. NOTE: A detailed assessment of HIV and Hepatitis B/C medical history must be done at screening for all patients. HIV 1/2 antibodies, HBsAg and HCV Ab Screen w/Reflex testing are required at screening for all patients.
  • Patients weighing <30kg will be excluded from enrollment
  • History of allogenic organ transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04108481


Contacts
Layout table for location contacts
Contact: Pashtoon Kasi, MD, MS 319-353-7899 pashtoon-kasi@uiowa.edu
Contact: Michelle Arnold, BSN 319-356-2778 michelle-arnold@uiowa.edu

Locations
Layout table for location information
United States, Iowa
University of Iowa Hospitals and Clinics Not yet recruiting
Iowa City, Iowa, United States, 52242
Contact: Pashtoon Kasi, MD, MS    319-353-7899    pashtoon-kasi@uiowa.edu   
Contact: Michelle Arnold, BSN    319-356-2778    michelle-arnold@uiowa.edu   
Sponsors and Collaborators
University of Iowa
Biocompatibles UK Ltd
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Pashtoon Kasi, MD, MS University of Iowa

Layout table for additonal information
Responsible Party: Pashtoon Murtaza Kasi, MD, MS, Clinical Assistant Professor, University of Iowa
ClinicalTrials.gov Identifier: NCT04108481     History of Changes
Other Study ID Numbers: 201909709
First Posted: September 30, 2019    Key Record Dates
Last Update Posted: September 30, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Pashtoon Murtaza Kasi, MD, MS, University of Iowa:
Immunotherapy
Colorectal Cancer
Y90
Y90-RE
Radioembolization
Y90-Radioembolization
y-90
Yttrium
Yttrium-90
Microsatellite Stable
MSS
CRC
mCRC
Colorectal
Liver Metastases
Liver Metastasis
Durvalumab
Anti-PD1
Anti-PDL1
Mismatch repair proficient
pMMR
KRAS
NRAS
BRAF
BRAF-V600E
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Colonic Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Rectal Neoplasms
Liver Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents
Adenocarcinoma
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Carcinoma
Neoplastic Processes
Pathologic Processes
Liver Diseases
Durvalumab
Atezolizumab
Immunologic Factors
Antibodies, Monoclonal